Is SARS-CoV-2 vertical transmission still a current problem? A case report on a diagnosed SARS-CoV-2 infection with a positive sample of urines.
Main Article Content
Keywords
Newborn, vertical transmission, SARS-CoV-2, nasal swab, Polymerase Chain Reaction Sars-CoV2 test on urines.
Abstract
Background and aim: Current data suggest little to no possibility of original COVID-19 transmission in pregnant women to the fetus during pregnancy or childbirth. Warning with Omicron new variants has decreased.
Case report: A clinical case of a SARS-CoV-2 virus transplacental infection of a newborn, born at the end of 2022, from a mother who tested positive for Sars-covid-2 and positive IgM SARS-CoV-2 anti-virus. The newborn tested positive for SARS-CoV-2 12 hours after birth, and was clinically symptomatic after three days, an increase in IgM antibodies was not found, although the virus was identified in the urine samples through molecular tests. The insufficient time to determine the presence of antibodies and the immune system’s state of immaturity can explain the lack of IgM in the newborn’s blood at 14 days after birth.
Conclusions: The Omicron SARS-CoV-2 keeps provoking infections among newborns, especially if the mother contracts it during the third trimester. The host response is most likely influenced by the newborn’s peculiar state of immune immaturity. Just before birth, a positive nasal swab and the presence of a positive urine examination confirmed the diagnosis of intraplacental exposure. Research on the virus through molecular tests of urines can represent an additional technique when an aetiological framework of the infection is necessary and a distinction between congenital and post-natal forms.
Downloads
References
World Health Organization, Technical documents. Available at: https://apps.who.int/iris/handle/10665/339422.
2 Allotey J, Chatterjee S, Kew T, et al. SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis BMJ 2022; 376:e067696 doi:10.1136/bmj-2021-067696
3 Pietrasanta C, Artieri G, Ronchi A, et al. SARS-CoV-2 infection and neonates: Evidence-based data after 18 months of the pandemic. Pediatr Allergy Immunol. 2022;33 (Suppl 27):96-98. doi: 10.1111/pai.13643. PMID: 35080307; PMCID: PMC9305748.
4 Istituto Superiore di Sanità Ministero della Salute della Repubblica Italiana. Covid19: flash survey Iss, l’8 novembre la variante Omicron al 99,8% . 2022. Comunicato Stampa N°78/2022 Available from: https://www.iss.it/-/comunicato-stampa-n%C2%B078/2022-covid19-flash-survey-iss-l-8-novembre-la-variante-omicron-al-99-8-
5 Lorenzo-Redondo R, Ozer EA, Hultquist JF. Covid-19: is omicron less lethal than delta? BMJ (Clinical research ed.) 2022;378: o1806. https://doi.org/10.1136/bmj.o1806
6 Bellos I, Pandita A, Panza R. Maternal and perinatal outcomes in pregnant women infected by SARS-CoV-2: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021; 256: 194–204. https://doi.org/10.1016/j.ejogrb.2020.11.038
7 Sammartano A, Testa G, Ippolito L. Maintainance of diagnostic Laboratory during pandemic emergency (SARS-CoV-2) in a Small Hospital. Acta Biomed 2022; 93(6): e2022325. https://doi.org/10.23750/abm.v93i6.13418
8 Kyle MH, Hussain M, Saltz V, Mollicone I, Bence M, Dumitriu D. Vertical Transmission and Neonatal Outcomes Following Maternal SARS-CoV-2 Infection During Pregnancy. Clin J Obstet Gynecol 2022; 65(1): 195–202. https://doi.org/10.1097/GRF.0000000000000667
9 Shook LL, Sullivan EL, Lo JO, Perlis RH, Edlow AG. COVID-19 in pregnancy: implications for fetal brain development. Trends Mol. Med. 2022: 28(4): 319–330. https://doi.org/10.1016/j.molmed.2022.02.004
10 Rubio R, Aguilar R, Bustamante M, et al. Maternal and neonatal immune response to SARS-CoV-2, IgG transplacental transfer and cytokine profile. Front. Immunol 2022; 13: 999136. https://doi.org/10.3389/fimmu.2022.999136
11 Anjos, D., Fiaccadori, F. S., Servian, SARS-CoV-2 loads in urine, sera and stool specimens in association with clinical features of COVID-19 patients. J Clin Virol 2022; 2(1): 100059. https://doi.org/10.1016/j.jcvp.2021.100059
12 Marchi L, Vidiri A, Fera EA, et al. SARS-CoV-2 IgG "heritage" in newborn: A credit of ma-ternal natural infection. J Med Virol. 2023 Jan;95(1):e28133. doi: 10.1002/jmv.28133.
13 De Souza SP, Silveira MAD, Souza BSF, et al. Evaluation of urine SARS-COV-2 RT-PCR as a predictor of acute kidney injury and disease severity in patients with critical COVID-19. J Int Med Res 2021; 49(5): 3000605211015555. https://doi.org/10.1177/03000605211015555
14 Moza A, Duica F, Antoniadis P, et al. Outcome of Newborns with Confirmed or Possible SARS-CoV-2 Vertical Infection-A Scoping Review. Diagnostics (Basel, Switzerland), 2023,13(2), 245. https://doi.org/10.3390/diagnostics1302024
15 Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 2012;37(5): 771–783. https://doi.org/10.1016/j.immuni.2012.10.0145
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
